Experienced in Chronic B-Cell Leukemia (CBCL)

Wolfgang Willenbacher

Innsbruck, AT 
Experienced in Chronic B-Cell Leukemia (CBCL)
Innsbruck, AT 
OverviewLocationsClinical Research

Overview

Wolfgang Willenbacher practices in Innsbruck, Austria. Mr. Willenbacher is rated as an Experienced expert by MediFind in the treatment of Chronic B-Cell Leukemia (CBCL). His top areas of expertise are Multiple Myeloma, Classical Hodgkin Lymphoma, Hodgkin Lymphoma, Waldenstrom Macroglobulinemia, and Bone Marrow Transplant.

His clinical research consists of co-authoring 85 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Chronic B-Cell Leukemia (CBCL).

Gender
Male

Locations

Innsbruck, Austria
Other Locations
Salzburg, Austria
Tirol, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Isatuximab in Combination With Lenalidomide-Dexamethasone Compared to Lenalidomide-Dexamethasone in Elderly Patients (Aged ≥70 Years) With Newly Diagnosed Myeloma: a Randomized Phase II Study (SGZ-2019-12650)
Isatuximab in Combination With Lenalidomide-Dexamethasone Compared to Lenalidomide-Dexamethasone in Elderly Patients (Aged ≥70 Years) With Newly Diagnosed Myeloma: a Randomized Phase II Study (SGZ-2019-12650)
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2025
Intervention Type: Drug
Study Drugs: Isatuximab-Irfc [Sarclisa], Lenalidomide, Dexamethasone Oral
Study Phase: Phase 2
A Window of Opportunity Trial With Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma or Patients Ineligible for Chemotherapy
A Window of Opportunity Trial With Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma or Patients Ineligible for Chemotherapy
Enrollment Status: Terminated
Publish Date: March 03, 2022
Intervention Type: Drug
Study Drugs: Brentuximab, Imatinib
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

85 Total Publications

Practice variations in indication, timing and outcome of Multiple Myeloma patients undergoing surgery for vertebral lesions - results from the European M2Spine study group.
Practice variations in indication, timing and outcome of Multiple Myeloma patients undergoing surgery for vertebral lesions - results from the European M2Spine study group.
Journal: Journal of neuro-oncology
Published: April 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Willenbacher's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile